scholarly journals Poor Cervical Cancer Screening Attendance and False Negatives. A Call for Organized Screening

PLoS ONE ◽  
2016 ◽  
Vol 11 (8) ◽  
pp. e0161403 ◽  
Author(s):  
Marta Castillo ◽  
Aurora Astudillo ◽  
Omar Clavero ◽  
Julio Velasco ◽  
Raquel Ibáñez ◽  
...  
2014 ◽  
Vol 136 (6) ◽  
pp. E677-E684 ◽  
Author(s):  
Anni Virtanen ◽  
Ahti Anttila ◽  
Tapio Luostarinen ◽  
Nea Malila ◽  
Pekka Nieminen

2015 ◽  
Vol 39 (6) ◽  
pp. 870-876 ◽  
Author(s):  
Aline Richard ◽  
Sabine Rohrmann ◽  
Seraina M. Schmid ◽  
Brigitte Frey Tirri ◽  
Dorothy J. Huang ◽  
...  

1990 ◽  
Vol 45 (3) ◽  
pp. 410-415 ◽  
Author(s):  
Marc A. Koopmanschap ◽  
Gerrit J. van Oortmarssen ◽  
Heleen M. A. van Agt ◽  
Marjolein van Ballegooijen ◽  
J. Dik F. Habbema ◽  
...  

2021 ◽  
Vol 29 (2) ◽  
pp. 90-95
Author(s):  
Anna Altová ◽  
Ivana Kulhánová ◽  
Lukáš Brůha ◽  
Michala Lustigová

2019 ◽  
Vol 22 ◽  
pp. S528
Author(s):  
A. Pakai ◽  
V. Péter ◽  
Z. Kívés ◽  
R. Vajda ◽  
T. Csákvári ◽  
...  

2014 ◽  
Vol 56 (5) ◽  
pp. 502 ◽  
Author(s):  
Víctor Granados-García ◽  
Yvonne N Flores ◽  
Ruth Pérez ◽  
Samantha E Rudolph ◽  
Eduardo Lazcano-Ponce ◽  
...  

Objective. To estimate the annual cost of the National Cervical Cancer Screening Program (CCSP) of the Mexican Institute of Social Security (IMSS). Materials and methods. This cost analysis examined regional coverage rates reported by IMSS. We estimated the number of cytology, colposcopy, biopsy and pathology evaluations, as well as the diagnostic test and treatment costs for cervical intraepithelial neoplasia grade II and III (CIN 2/3) and cervical cancer. Diagnostic test costs were estimated using a micro-costing technique. Sensitivity analyses were performed. Results. The cost to perform 2.7 million cytology tests was nearly 38 million dollars, which represents 26.1% of the total program cost (145.4 million). False negatives account for nearly 43% of the program costs. Conclusion. The low sensitivity of the cytology test generates high rates of false negatives, which results in high institutional costs from the treatment of undetected cervical cancer cases.


BMJ Open ◽  
2019 ◽  
Vol 9 (2) ◽  
pp. e024011 ◽  
Author(s):  
Ditte Søndergaard Linde ◽  
Vibeke Rasch ◽  
Julius D Mwaiselage ◽  
Tine M Gammeltoft

ObjectivesThe aim of this study was to understand causes of attendance and non-attendance to a follow-up cervical cancer screening among human papillomavirus (HPV)-positive women.DesignSemistructured, individual interviews with HPV-positive women and cervical cancer screening nurses. The interview guide and initial data analysis were guided by existing health behaviour theories. However, as the theories limited the potential of the data material, a grounded theory framework guided the final data analysis.SettingInterviews were conducted in Dar es Salaam, Tanzania, at Ocean Road Cancer Institute (ORCI) or in the homes of screening clients.Participants15 interviews were conducted with women who had tested HPV-positive during a patient-initiated screening and been appointed for a follow-up screening 14 months later. Nine women had not attended the follow-up appointment, four had delayed attendance and two had attended on the scheduled date. Further, individual interviews were conducted with the two nurses working at ORCI’s screening clinic.ResultsPerceived benefits for attending a patient-initiated screening include treatment of gynaecological symptoms and prevention of disease. The key perceived benefit of a health provider-initiated follow-up screening is prevention, which is challenged by the circumstance that it is seen by women as having merely potential benefit and therefore can be postponed when competing needs are present. Perceived challenges for screening attendance include emotional costs, in the form of fear of the disease, fear of the gynaecological examination as well as direct and indirect economic costs, such as transportation costs, lost income and waiting time.ConclusionCervical cancer screening is one among many tasks that women living in a low-income setting must attend to. Since health provider-initiated follow-up screening is seen as having only potential benefit, attendance can be postponed when competing needs exist.Trial registration numberNCT02509702.


Sign in / Sign up

Export Citation Format

Share Document